Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for adverse events
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study) We sought to develop a multiple biomarker approach for prediction of incident major adverse cardiac events (MACE; composite of cardiovascular death, myocardial infarction, and stroke) in patients referred for coronary angiography. In a 649-participant training
Beta-blocker subtype and risks of perioperative adverseevents following non-cardiac surgery: a nationwide cohort study Beta-blockers vary in pharmacodynamics and pharmacokinetic properties. It is unknown whether specific types are associated with increased perioperative risks. We evaluated perioperative risks associated with beta-blocker subtypes, overall and in patient subgroups.We performed a Danish Nationwide cohort study, 2005-2011, of patients treated chronically with beta blocker (...) (atenolol, bisoprolol, carvedilol, metoprolol, propranolol, or other) prior to non-cardiac surgery. Risks of 30-day all-cause mortality (ACM) and 30-day major adverse cardiovascular events (MACE) were estimated using adjusted logistic regression models and odds ratios with 95% confidence intervals. We identified 61 660 patients, most frequently treated with metoprolol (67% of patients, mean age 69 years, 49% males), atenolol (10% of patients, mean age 68 years, 36% males), or carvedilol (9% of patients
Self reported outcomes and adverseevents after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland. Objectives To assess self reported outcomes and adverseevents after self sourced medical abortion through online telemedicine.Design Population based study.Setting Republic of Ireland and Northern Ireland, where abortion is unavailable through the formal healthcare system except in a few restricted circumstances.Population 1000 (...) women who underwent self sourced medical abortion through Women on Web (WoW), an online telemedicine service, between 1 January 2010 and 31 December 2012.Main outcome measures Successful medical abortion: the proportion of women who reported ending their pregnancy without surgical intervention. Rates of adverseevents: the proportion who reported treatment for adverseevents, including receipt of antibiotics and blood transfusion, and deaths reported by family members, friends, or the authorities
Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration AdverseEvent Reporting System. Direct-acting antiviral agents (DAAs) are used increasingly to treat hepatitis C virus (HCV) infection. Reports were published recently on hepatitis B virus (HBV) reactivation (HBV-R) in patients with HBV-HCV co-infection. Hepatitis B virus reactivation, defined as an abrupt increase (...) in HBV replication in patients with inactive or resolved HBV infection, may result in clinically significant hepatitis.To assess whether HBV-R is a safety concern in patients receiving HCV DAAs.Descriptive case series.U.S. Food and Drug Administration (FDA) AdverseEvent Reporting System (FAERS).29 patients with HBV-R receiving HCV DAAs.Clinical and laboratory data.The FDA identified 29 unique reports of HBV-R in patients receiving DAAs from 22 November 2013 to 15 October 2016. Two cases resulted
Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverseevents study Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverseevents study Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverseevents study Mayor S, Baines E, Vincent C, Lankshear A, Edwards A, Aylward M, Hogan H, Harper P, Davies J, Mamtora A, Brockbank E & Gray J Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mayor S, Baines E, Vincent C, Lankshear A, Edwards A, Aylward M, Hogan H, Harper P, Davies J, Mamtora A, Brockbank E & Gray J. Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverseevents study. Health Services and Delivery Research 2017; 5(9) Authors' objectives Despite
Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation: A pre-specified analysis from the randomized minimizing adverse haemorrhagic events by transradial access site and systemic implementation of angi To assess whether radial compared with femoral access is associated with consistent outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS).In the Minimizing (...) Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX) programme patients were randomized to radial or femoral access, stratified by STEMI (2001 radial, 2009 femoral) and NSTE-ACS (2196 radial, 2198 femoral). The 30-day co-primary outcomes were major adverse cardiovascular events (MACE), defined as death, myocardial infarction, or stroke, and net adverse clinical events (NACE), defined as MACE or major bleeding In the overall study population, radial
Adverseevents in a chiropractic spinal manipulative therapy single-blinded, placebo, randomized controlled trial for migraineurs. Unlike pharmacological randomized controlled trials (RCTs), manual-therapy RCTs do not always report adverseevents (AEs). The few manual-therapy RCTs that provide information on AEs are frequently without details, such as the type and-, severity of the AE and reason for withdrawal.To prospectively report all AEs in a chiropractic spinal manipulative therapy (CSMT
Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverseevents study Measuring harm and informing quality improvement in the Welsh NHS: the longitudinal Welsh national adverseevents study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find
Preventing drug-related adverseevents following hospital discharge: the role of the pharmacist Transition of care (ToC) points, and in particular hospital admission and discharge, can be associated with an increased risk of adverse drug events (ADEs) and other drug-related problems (DRPs). The growing recognition of the pharmacist as an expert in medication management, patient education and communication makes them well placed to intervene. There is evidence to indicate that the inclusion
Trends in Perioperative Major Adverse Cardiovascular and Cerebrovascular Events associated with Non-Cardiac Surgery Major adverse cardiovascular and cerebrovascular events (MACCE) are a significant source of perioperative morbidity and mortality following noncardiac surgery.To evaluate national trends in perioperative cardiovascular outcomes and mortality after major noncardiac surgery and to identify surgical subtypes associated with cardiovascular events using a large administrative database (...) occurred in 317 479 hospitalizations (3.0%), corresponding to an annual incidence of approximately 150 000 events after applying sample weights. Major adverse cardiovascular and cerebrovascular events occurred most frequently in patients undergoing vascular (7.7%), thoracic (6.5%), and transplant surgery (6.3%). Between 2004 and 2013, the frequency of MACCE declined from 3.1% to 2.6% (P for trend <.001; adjusted odds ratio [aOR], 0.95; 95% CI, 0.94-0.97) driven by a decline in frequency
The effect of endotracheal tubes versus laryngeal mask airways on perioperative respiratory adverseevents in infants: a randomised controlled trial. Perioperative respiratory adverseevents (PRAE) are the most common critical incidents in paediatric anaesthesia and occur more often in infants. Use of laryngeal mask airways (LMAs) is associated with reduced PRAE compared with endotracheal tubes in older children (>1 year). We aimed to evaluate the effect of these devices on the incidence
2017LancetControlled trial quality: predicted high
In adults with ankle osteoarthritis (OA), is total ankle replacement/fusion/debridement better than no treatment for pain and function, risks and harms and adverseevents? Getting Evidence into Clinical Practice: Musculoskeletal Research Facilitation Group (CAT Group) Date: February 2018 CAT Lead: Jo Pike Date CAT completed: February 2018 firstname.lastname@example.org Date CAT to be reviewed: February 2021 Specific Question: In adults with ankle Osteoarthritis (OA) A is total ankle replacement/fusion (...) /debridement better than no treatment for pain and function, risks and harms and adverseevents? Clinical bottom line At present, there are no studies that compare surgical intervention with no treatment for the management of patients with ankle OA. Due to the lack of evidence of comparing no treatment with surgical intervention for pain and function, risks and harms and adverseevents, then clinical practice should remain unchanged. Within the available evidence, it is apparent that surgical intervention
Adverseevents associated with ERCP GUIDELINE Adverseevents associated with ERCP Prepared by: ASGE STANDARDS OF PRACTICE COMMITTEE Vinay Chandrasekhara, MD, Mouen A. Khashab, MD, V. Raman Muthusamy, MD, FASGE, Ruben D. Acosta, MD, Deepak Agrawal, MD, MPH, David H. Bruining, MD, Mohamad A. Eloubeidi, MD, MHS, FASGE, Robert D. Fanelli, MD, FACS, FASGE, SAGES Representative, Ashley L. Faulx, MD, FASGE, Suryakanth R. Gurudu, MD, FASGE, Shivangi Kothari, MD, Jenifer R. Lightdale, MD, MPH, FASGE (...) consider the clinical appropriateness of ERCP, it is important for them to have a thorough understanding of available alter- natives and of the potential adverseevents associated with the procedure. In addition, they must understand and attempt to follow maneuvers that reduce the risk of adverseevents. Early recognition and appropriate manage- ment of potential adverseevents are critical to reducing morbidity and mortality associated with the procedure. The diagnosis and management of all adverse
In patients with non-operatively (conservatively) managed to tendo-achilles (TA) ruptures, is accelerated rehabilitation superior to routine rehabilitation for reducing pain and return to function time, without increasing adverseevents of tendon lengthen Getting Evidence into Clinical Practice: Musculoskeletal Research Facilitation Group (CAT Group) Date:19.11.2016 CAT Lead: Fraser Philp Date CAT completed: 19.11.2016 Email: email@example.com Date CAT to be reviewed: 19.11.2018 Specific (...) Question: In patients with non-operatively (conservatively) managed tendo-achilles (TA) ruptures, is accelerated rehabilitation superior to routine rehabilitation for reducing pain and return to function time, without increasing adverseevents of tendon lengthening and re-rupture rates? Clinical bottom line In patients with non-operatively (conservatively) managed TA ruptures, there is no evidence that compares an accelerated rehabilitation programme against routine rehabilitation. Within the papers
Adverseevents after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study. Concerns have been raised about the safety of surgery for stress urinary incontinence and pelvic organ prolapse using transvaginal mesh. We assessed adverse outcomes after first, single mesh procedures and comparable non-mesh procedures.We did a cohort study of women in Scotland aged 20 years or older
Crizotinib-Induced Fulminant Hepatic Failure: A Rare AdverseEvent 30241172 2019 03 04 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Crizotinib-Induced Fulminant Hepatic Failure: A Rare AdverseEvent. 1-4 10.1200/JGO.2016.007765 Adhikari Narayan N All authors: All India Institute of Medical Sciences, New Delhi, Delhi, India. Kumar Pavnesh P All authors: All India Institute of Medical Sciences, New Delhi, Delhi, India. Venkatesulu Bhanu P BP All authors: All India Institute
Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and AdverseEvents Anthrax postexposure prophylaxis (PEP) was recommended to 42 people after a laboratory incident that involved potential aerosolization of Bacillus anthracis spores in 2 laboratories at the Centers for Disease Control and Prevention in 2014. At least 31 (74%) individuals who initiated PEP did not complete either the recommended 60 days of antimicrobial therapy or the 3-dose vaccine regimen. Among the 29 (...) that discontinued the antimicrobial component of PEP, most (38%) individuals discontinued PEP because of their low perceived risk of infection; 9 (31%) individuals discontinued prophylaxis due to PEP-related minor adverseevents, and 10% cited both low risk and adverseevents as their reason for discontinuation. Most minor adverseevents reported were gastrointestinal complaints, and none required medical attention. Individuals taking ciprofloxacin were twice as likely (RR = 2.02, 95% CI = 1.1-3.6